Key Points - Rosen Law Firm reminds investors of the lead plaintiff deadline for the class action lawsuit against Hyliion Holdings Corp. - Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Hyliion on behalf of investors who suffered losses during the Class Period. - Glancy Prongay Wolke & Rotter LLP announces...
Rather than pick a side, this is the evidence on each. National Bankshares, Inc. (NKSH) currently...
Rather than pick a side, this is the evidence on each. CytomX Therapeutics, Inc. (CTMX) currently...
Rather than pick a side, this is the evidence on each. NN, Inc. (NNBR) currently shows...
Rather than pick a side, this is the evidence on each. Vanda Pharmaceuticals Inc. (VNDA) currently...
from Barclays issued a price target of $1.00 for EVTL on 2026-10-08 20:26:18.The adjusted price target was set to $1.00.At the time of the announcement, EVTL was trading at $0.5443.The...
from Seaport Global issued a price target of $422.00 for DAVE on 2026-10-08 13:59:09.The adjusted price target was set to $422.00.At the time of the announcement, DAVE was trading at...
from Oppenheimer issued a price target of $115.00 for GHM on 2026-10-08 11:44:40.The adjusted price target was set to $115.00.At the time of the announcement, GHM was trading at $84.34.The...
Kambiz Yazdi from Jefferies issued a price target of $39.00 for ARQT on 2026-10-08 08:23:00.The adjusted price target was set to $39.00.At the time of the announcement, ARQT was trading...
Adam Kroll from Piper Sandler issued a price target of $20.00 for LCNB on 2026-10-08 07:52:00.The adjusted price target was set to $20.00.At the time of the announcement, LCNB was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
